Business Wire

Neustar DNS Shield Wins “Innovative Product of the Year” at the Prestigious Cyber Security Awards Dinner

3.7.2017 13:03 | Business Wire

Jaa

Neustar, Inc. (NYSE:NSR), a trusted, neutral provider of real-time information services, today announced that its ground-breaking DNS Shield(TM) solution has won the “Innovative Product of the Year” category at the 2017 Cyber Security Awards.

Rodney Joffe, Neustar SVP, Fellow, and DNS Shield creator said: "Our DNS Shield platform is designed to increase the resilience of our DNS infrastructure beyond the levels attainable by any other current technology. Under most circumstances, our DNS Shield nodes are impervious to disruption from DDoS attacks and global Internet disruptions that would cause other DNS systems to fail catastrophically. Growing the DNS Shield platform is a key component to our security architecture. We are already protecting over three hundred million consumers and businesses, spread across a number of major Service Provider Partners from DNS outages, and ensuring unparalleled DNS security and reliability for thousands of customers. We are delighted that the Cyber Security Awards' judges recognise the value of DNS Shield and the innovation behind its development."

DNS Shield reengineers the Internet by hardwiring private network connections between its authoritative servers and its partner’s recursive servers. The judges recognized this radically different industry-first approach in selecting Neustar as the award winner.

Now in their third year, the Cyber Security Awards are independent of any industry affiliations and open to all organizations that are committed to furthering the security industry. With the aim of rewarding the best individuals, teams, and companies within the cyber security industry, every category is judged on excellence and innovation. The judging panel includes senior executives, security professionals and academics from a range of organizations including, Credit Suisse, Aviva, Warwick University and Executive Risk Magazine.

The winners were announced at a glittering black-tie ceremony on June 29th at the Chelsea Harbour Hotel in central London.

About Neustar Security Solutions

Neustar Security Solutions defend against network threats, inform you of potential network vulnerabilities, accelerate online asset performance, and monitor client website performance through multiple services and offerings. Neustar will offer the largest, most distributed DDoS mitigation network in the world with over 10 Tbps of capacity, and our industry leading SiteProtect DDoS protection service ensures full coverage in an attack. Our UltraDNS service manages 10 percent of all internet traffic, routes over 1T queries a month and provides industry leading uptime and 100 percent website availability. Neustar’s IP Intelligence is the authoritative source of IP decisioning data on 99.9 percent of routable IP addresses worldwide. Our 19+ years of unparalleled expertise ensures that our customers are protected and optimized during normal business practices and when unsolicited events occur. Our services ensure customers network connectivity are protected and optimized whether in crisis or just business as usual. We are trusted by many of the world’s largest brands to keep their mission critical systems up and running.

About Neustar

Every day, the world generates roughly 2.5 quadrillion bits of data. Neustar (NYSE:NSR) isolates certain elements and analyzes, simplifies and edits them to make precise and valuable decisions that drive results. As one of the few companies capable of knowing with certainty who is on the other end of every interaction, we’re trusted by the world’s great brands to make critical decisions some 20 billion times a day. We help marketers send timely and relevant messages to the right people. Because we can authoritatively tell a client exactly who is calling or connecting with them, we make critical realtime responses possible. And the same comprehensive information that enables our clients to direct and manage orders also stops attackers. We know when someone isn’t who they claim to be, which helps stop fraud and denial of service before they’re a problem. Because we’re also an experienced manager of some of the world’s most complex databases, we help clients control their online identity, registering and protecting their domain name, and routing traffic to the correct network address. By linking the most essential information with the people who depend on it, we provide more than 11,000 clients worldwide with decisions—not just data. More information is available at https://www.neustar.biz

Contact information

Neustar Media Contact
Laura Cahill
Laura.cahill@axicom.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®27.7.2017 16:00Tiedote

Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40mg/0.8mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. The study will compare the pharmacokinetics and clinical outcomes between patients receiving Humira® continuously, versus those who switch repeatedly between Humira® and BI 695501, Boehringer Ingelheim’s adalimumab biosimilar candidate.1 The study will also assess safety, immunogenicity and efficacy.1 “We are pleased that the first patient has now been enrolled in VOLTAIRE-X, and look forward to continued recruitment and patient follow-up,” said Ivan Blanarik, Senior Vice President and Head of

Acxiom Launches Connected Spaces27.7.2017 15:30Tiedote

Today, Acxiom® (Nasdaq: ACXM), in collaboration with Adobe, announced the launch of Connected Spaces, a global solution aimed at delivering more relevant omnichannel experiences to customers. Connected Spaces is designed to revolutionise customer experience and business returns for retail, travel and leisure locations such as airports, malls, sports stadiums, concert arenas and resorts. A pioneering example is Heathrow airport. Heathrow is able to deliver more relevant communications to customers in real-time as part of its overall engagement strategy and is already generating exceptional results including an increase in spend of 20-25 percent for engaged customers. Common to airports, malls and the like is a high footfall of consumers who intend to visit multiple concession, franchise, or subcontracted brands operating in their environments. This can translate to a relative

Watch BizWireTV: Helix Brings DNA Kits to the Public and Michael Kors Gets Ready to Buy Jimmy Choo27.7.2017 15:08Tiedote

On the latest BizWireTV, catch the latest Quick Biz Hits. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170727005456/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Helix launches first online consumer marketplace for DNA-powered products that offer insights on ancestry, entertainment, family, fitness, health and nutrition. Watch BizWireTV to

European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria27.7.2017 14:05Tiedote

Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases, announced today that the European Commission has granted orphan drug designation to Allena’s investigational product ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH). The orphan designation was granted to Allena Pharmaceuticals Ireland Limited, a subsidiary of Allena Pharmaceuticals, Inc. Allena’s lead compound ALLN-177, is being developed to treat patients with severe hyperoxaluria, a condition characterized by markedly elevated urinary oxalate excretion. PH, a type of severe hyperoxaluria, is a rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney

Subscription Period for Superior Industries’ Tender of UNIWHEELS AG’s Shares to Close Monday, July 31, 201727.7.2017 09:00Tiedote

Superior Industries International, Inc. (NYSE:SUP), one of the world’s largest manufacturers of aluminum wheels, reiterated today that the subscription period for the tender offer to acquire all remaining outstanding shares of UNIWHEELS AG (“UNIWHEELS”) will close Monday, July 31, 2017. On June 30, 2017, Superior announced it had commenced a tender offer to acquire the remaining 954,920 shares held by the public shareholders, which represents approximately 7.7% of the total outstanding shares of UNIWHEELS, for cash consideration of 247.87zl per share. Superior acquired the other approximately 92.3% of the outstanding shares through a tender offer that was settled on May 30, 2017, where the public shareholders also received cash consideration of 247.87zl per share. Following the settlement of the tender offer, Superior will finalize the proceedings to delist UNIWHEELS’ common stock from

Ipsen Delivers Strong Sales Growth of 18.8%1 in the First Half of 2017 and Upgrades Its Guidance for Full Year 201727.7.2017 08:00Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first half of 2017. H1 2017 Highlights Strong operating performance of 18.8%1 Group sales growth and Core Operating Income margin improvement by 1.2 points to 26.2% of sales Specialty Care sales growth of 23.1%1 reflects continued Somatuline® momentum and includes contribution of key new products Cabometyx® and Onivyde® Consumer Healthcare sales growth of 1.3%1 including contribution of newly acquired products Upgraded full year 2017 guidance of Specialty Care sales growth greater than 24.0%1, slight growth1 of Consumer Healthcare sales, and Core Operating Income margin greater than 25.0% o

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme